Hepatocellular carcinoma (HCC) is the third cause of cancer-related death worldwide. When these tumors are in advanced stages, few therapeutic options are available. Therefore, it is essential to search for new treatments to fight this disease. In this study, we investigated the effects of cannabinoids -a novel family of potential anticancer agents -on the growth of HCC. We found that D
Hepatocellular carcinoma (HCC) is one of the most common solid tumors and the third leading cause of cancer-related death worldwide. 1 Its prognosis remains reserved, with a 5-year survival rate of o5%.
2 It is the most common cause of death in patients with cirrhosis 3 and, according to the World Health Organization, the incidence of HCC is expected to increase until 2030. The overall survival of patients with HCC has not significantly improved in the past two decades. Current treatments are only applicable at early stages of tumor development and include tumor resection, liver transplantation, chemoembolization and sorafenib administration. 4 However, approximately half of the patients suffer tumor recurrence. The most important mechanism of liver cancer progression is cell proliferation. Although in recent years several clinical trials have tested the efficacy of agents that selectively target important signaling pathways involved in the control of this process, no relevant improvement in the prognostic/survival of patients with HCC has been achieved so far, 5 and, therefore, it is necessary to identify novel therapeutic strategies for the management of HCC.
Cannabinoids are lipid mediators originally isolated from the hemp plant Cannabis sativa that produce their effects by activating primarily two G-protein-coupled receptors: cannabinoid receptor 1 (CB 1 ), which is highly abundant in the brain, and cannabinoid receptor 2 (CB 2 ), which is mainly expressed in non-neural tissues. Recently, numerous studies have evidenced the role of cannabinoids as potential anti-tumoral drugs owing to their ability to reduce tumor in different animal models, including glioma, 6 breast cancer 7, 8 and prostate cancer. 9, 10 Recent research has also reported that the synthetic cannabinoid WIN-55 212-2 inhibits HCC growth. 11, 12 It has been described that D 9 -tetrahydrocannabinol (D 9 -THC), the main active constituent of marijuana, triggers human glioma cell death through stimulation of an ER stress pathway that activates autophagy and promotes apoptosis. 13, 14 Autophagy is a cellular self-digestive process whereby bulk cytoplasmic components and intracellular organelles are sequestered into double-membrane vesicles named autophagosomes and delivered for degradation to the lysosomes. 8, 15, 16 In the liver, autophagy may have an important role in the regulation of energy balance for basic cell functions. 17 Although functional autophagy acts as a metabolic stress buffer, many lines of evidence support a role for autophagy in antagonizing cell survival and in promoting cell death and apoptosis. [18] [19] [20] Autophagy has an important role in cancer, and inhibition of this cellular process has been proposed to contribute to HCC progression, 21, 22 and, therefore, it is a potentially very important target for liver cancer prevention and treatment.
This study was therefore undertaken to evaluate the potential anti-tumoral activity of cannabinoids in HCC and the mechanisms responsible for cannabinoid action in that devastating disease. We found that, both in cell cultures and in xenografted mice, D
9
-THC and the synthetic CB 2 receptor-selective agonist JWH-015 promote human HCC death via autophagy stimulation. We also provide a molecular mechanism underlying CB 2 receptor-mediated anti-tumoral signaling. These observations may pave the way to the design of novel therapeutic strategies for the treatment of hepatocellular carcinoma.
Results

D
9
-THC-and JWH-015-induced autophagy and apoptosis relies on CB 2 receptor activation. To investigate the activity of cannabinoids on HCC cells, we first analyzed the effect of D
-THC (a CB 1 /CB 2 receptor-mixed agonist that constitutes the main psychoactive ingredient of Canabis sativa) and JWH-015 (a CB 2 receptor-selective agonist) on HepG2 (human hepatocellular liver carcinoma cell line) and HuH-7 (hepatocellular carcinoma cells) cells, two HCC lines that express CB 1 and CB 2 cannabinoid receptors (Supplementary Figure 1A) . Treatment with D
-THC reduced the viability of HepG2 and HuH-7 cells, an event that was prevented by coincubation with SR144528 (SR2, a CB 2 receptor-selective antagonist), but not with SR141716A (SR1, a CB 1 receptorselective antagonist) (Supplementary Figure 1B) . Likewise, JWH-015 decreased the viability of HCC cells, and coincubation with SR2 abrogated this effect (Supplementary Figure 1B) . These observations support that stimulation of CB 2 receptors is responsible for the decrease of cell viability triggered by cannabinoids on HCC cells.
D
9 -THC and JWH-015 inhibit the growth of the human HCC lines HepG2 and HuH-7 via autophagy stimulation. It has been recently shown that cannabinoids induce human glioma cell death via autophagy stimulation in vitro and in vivo. 13, 23 We therefore examined whether D 9 -THC and JWH-015 activate a similar mechanism in HCC cells. Upon autophagy stimulation, the autophagy protein LC3 (microtubule-associated protein 1 light chain 3a) becomes conjugated to phosphatidylethanolamine (PE), which targets this protein to the membrane of the autophagosomes. The lipidated autophagosome-associated form of LC3 (LC3-II) can be monitored by immunofluorescence (autophagic cells exhibit a characteristic pattern of LC3 puncta) or western blot (LC3-II has higher electrophoretic mobility than non-lipidated LC3). Immunofluorescence analysis revealed that LC3 exhibited a punctuated distribution, consistent with its translocation to the autophagosome, in cells that had been treated with D 9 -THC or JWH-015 ( Figure 1a) . Likewise, incubation of HepG2 and HuH-7 cells with D
9
-THC or JWH-015 increased the levels of the lipidated form of LC3 (Figure 1b) . Furthermore, pharmacological inhibition with E64d and pepstatin A (PA) of lysosomal proteases (the enzymes responsible for the degradation of the autophagosome content after fusion with the lysosome) enhanced the accumulation of LC3-II (as well as of the autophagosome cargo p62) in cells that had been treated with THC or JWH-015, thus supporting the fact that cannabinoid treatment leads to dynamic autophagy in HCC cells (Figure 1b) .
Next, we investigated whether autophagy was directly involved in the mechanism of cannabinoid-induced cell death. As shown in Figure 1c , cell death was inhibited when autophagy was pharmacologically blocked at a very early stage (by incubation with 3-methyladenine (3-MA), an inhibitor of Vps34, a class III phosphatidyl inositol-3-kinase that has a crucial role in autophagy initiation 24 ) or at a final stage (by incubation with E64d and PA). Likewise, knock down of Atg5 (an essential autophagy gene that is part of one of the two protein conjugation systems required for autophagosome elongation 25, 26 ) impaired THC-or JWH-015-induced cell death (Figure 1d ). Taken together, these observations strongly support that autophagy is required for cannabinoidinduced HCC cell death.
Many lines of evidence indicate that there is a cross-talk between autophagy and apoptosis. 27 To investigate whether cannabinoid-induced autophagy was involved in apoptosis induction, HepG2 and HuH-7 cells were incubated with either D 9 -THC or JWH-015 in the presence of the 3-MA, and levels of procaspase-3 were detected by immunoblot. As shown in Figure 1e , pre-incubation with 3-MA prevented the cleavage of procaspase-3, suggesting that autophagy induction by cannabinoids was previous to and necessary for apoptosis.
AMPK activation and TRB3 upregulation are involved in D
-THC-and JWH-015-induced autophagy and apoptosis of HCC cells. The mechanisms of autophagy stimulation by cannabinoids in glioma and other types of cancer cells relies on the stimulation of an ER stress-related pathway, which leads to the upregulation of the pseudokinase tribbles homolog 3 (TRB3). This latter protein interacts with serine-threonine kinase Akt (Akt) and promotes the inhibition of the mammalian target of rapamycin C1 (mTORC1) complex, which leads to autophagy stimulation. 23 As shown in Figure 2 , THC and JWH-015 increased the phosphorylation of the a-subunit of the eukaryotic translation initiation factor 2 (eIF2a, a hallmark of the ER stress response; Figure 2a ), increased TRB3 levels ( Figure 2b ) and decreased the phosphorylation of Akt, p70S6 kinase (a well-established substrate of mTORC1) and the ribosomal protein S6 (a target of p70S6 kinase) in HepG2 and HuH-7 cells (Figure 2c ). Furthermore, selective knockdown of TRB3 abrogated cannabinoid-induced inhibition of the Akt/mTOR pathway, autophagy and cell death ( Supplementary Figure 2) , thus supporting the fact that the mechanism by which cannabinoids promotes glioma cell death also operates in HCC cells.
Of note, we observed that treatment of HepG2 and HuH-7 cells with THC or JWH-015 increased the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), an important intracellular nutrient status sensor that has been proposed to have a critical role in the regulation of autophagy as induced by hypoxia or nutrient deprivation AMPK and TRB3 regulate cannabinoid-induced autophagy of HCC cells through different mechanisms. AMPK has been shown to inhibit mTORC1. 28 Unlike Akt, AMPK activates tuberous sclerosis complex 2 (TSC2), a GTPase-activating protein responsible for the blockade of mTORC1. 28 Therefore, we next studied whether this was the mechanism by which AMPK stimulated autophagy in our system. As shown in Figure 3c and Supplementary Figure 2C Activation of AMPK by cannabinoids relies on CAMKK. We next investigated the mechanism by which cannabinoids activate AMPK. Among the different kinases proposed to act as AMPKKs, the human tumor suppressor liver kinase B1 (LKB1) and the calmodulin-activated kinase kinase (CaMKK) are now widely accepted as the most relevant ones. 30 Inhibition of LKB1 expression with siRNA did not have any significant effect on the viability of cannabinoidtreated HepG2 (Figure 4a Taken together, these observations robustly support the fact that cannabinoid anti-tumoral action in HCC relies on AMPK stimulation, Akt inhibition and activation of autophagy in HCC cells both in vitro and in vivo.
Discussion
In this study, we show that the natural cannabinoid D 9 -THC and the CB 2 receptor-selective agonist JWH-015 inhibit HCC Anti-tumoral action of cannabinoids on HCC D Vara et al cell growth via stimulation of autophagy. Importantly, although the human HCC cell lines used (HepG2 and HuH-7) expressed both CB 1 and CB 2 receptors, only CB 2 activation was involved in the pro-autophagic and antiproliferative effect induced by cannabinoids on these cells. This is in line with the recent observation that the synthetic cannabinoid WIN-55, 212-2-induced apoptosis in HepG2 cells in a process that was partially inhibited by the CB 2 receptor-selective antagonist AM630. 11 Moreover, it has been previously shown that CB 2 receptors are overexpressed in HCC and correlate with good prognosis. 31 Those findings, together with ours, support the fact that stimulation of CB 2 receptors could be a new therapeutic strategy to promote HCC death.
Our study shows that the mechanism of cannabinoid antitumoral action in HCC relies on the stimulation of autophagy and the subsequent activation of apoptosis. Depending on the physiopathological setting, autophagy has been proposed to protect from apoptosis, act as an apoptosis-alternative pathway to induce cell death or act together with apoptosis as a combined mechanism for cell death. 32 However, very little is known about the role that the interchange between these two cellular processes have in the control of tumor growth in response to anticancer agents. Our observations are in line with previous results obtained in human glioma cells 13 and support the fact that stimulation of autophagy in response to cannabinoid treatment leads to apoptosis. Nevertheless, further research is still necessary to clarify the precise mechanisms linking both cellular processes upon cannabinoid treatment.
Stimulation of autophagy in many cellular settings relies on the inhibition of the mTORC1 complex, which have a central role in the control of protein synthesis, cell growth and cell proliferation through the regulation of several downstream targets. As a result of its central position in the control of cellular homeostasis, mTORC1 integrates signals from different inputs. One of the most important upstream regulators of mTORC1 is the pro-survival kinase Akt, which phosphorylates and inactivates TSC2 (an inhibitor of the mTORC1 activator Rheb) and PRAS-40. Thus, Akt activation stimulates mTORC1 and inhibits autophagy. In this work, we found that cannabinoid treatment of HCC cells leads to Akt and mTORC1 inhibition, which is in agreement with our recent studies in glioma cells. 13 Thus, it had been previously shown that inhibition of Akt/mTORC1 pathway by cannabinoids relies on the stimulation of an ER stress-related pathway, which leads to the upregulation of the pseudokinase TRB3, the inhibition of the Akt/mTORC1 axis and the induction of autophagy. 13, 23 In this study, D 9 -THC and JWH-015 promoted ER stress and increased TRB3 expression. In addition, Akt/ mTORC1 inhibition and autophagy were abolished when ceramide biosynthesis was inhibited or when TRB3 expression was silenced, thus suggesting that this could be a general mechanism of cannabinoid anti-tumoral action. Of importance, we also found that D 9 -THC and JWH-015 activate AMPK in HCC cells and that pharmacological or genetic inhibition of this kinase has a similar inhibitory effect on cannabinoid-induced cell death and autophagy. AMPK has been shown to negatively regulate mTORC1 via TSC2 activation, which also leads to autophagy stimulation, 33 and therefore we asked whether cannabinoids also inhibit mTORC1 through this mechanism in HCC cells. In disagreement with this possibility, our data show that -unlike TRB3 silencing -AMPK knockdown does not prevent cannabinoidinduced mTORC1 inhibition. In addition, knock down of TRB3 does not affect the stimulation of AMPK by cannabinoids. These observations suggest that TRB3 and AMPK (i) are activated by different mechanisms in response to cannabinoid treatment, and (ii) regulate autophagy acting at different stages.
Two converging pathways have been described for AMPK regulation: one directed by LKB1, dependent on a change in cellular AMP, and another one directed by CaMKKs, dependent on changes in intracellular Ca 2 þ . 34 The dramatic reduction in phospho-AMPK and phospho-ACC obtained upon silencing of CaMKKb indicates that this latter kinase rather than LKB1 is the dominant AMPKK enzyme in HCC cells in response to cannabinoids. Thus, cannabinoids induce autophagy in HCC cells, possibly by a two-pronged mechanism, one prong (similar to that operating in glioma cells) involving ER stress, TRB3 and Akt/mTORC1 inhibition, and another one reliant on AMPK stimulation via CaMKKb. A model of this mechanism of cannabinoid action in HCC cells is depicted in Figure 5 .
In addition, it has been recently shown that AMPK binds to and directly phosphorylates the Ser/Thr kinase ULK1, the mammalian ortholog of the yeast protein kinase Atg1, and that this phosphorylation is required for ULK1-mediated autophagy. 35, 36 Thus, under certain cellular settings, mTORC1 inhibition and AMPK activation may cooperate to trigger autophagy. [36] [37] [38] Although future research is needed to completely clarify this point, our data suggest that this could be the mechanism by which cannabinoids trigger autophagy in HCC cells.
To note, it has been recently described that mTOR signaling has a critical role in the pathogenesis of HCC and that mTOR inhibitors have antineoplastic activity in experimental models of HCC. 39 Moreover, decreased autophagy in HCC correlates with a more aggressive cancer cell phenotype and poor prognosis. 21, 40 Here we found that cannabinoid treatment reduces the growth of two different models of HCC subcutaneous xenografts in concert with decreased mTORC1 activation, enhanced AMPK phosphorylation and increased autophagy and apoptosis in those tumors. Moreover, knock down of the autophagic gene Atg5 as well as pharmacological inhibition of autophagy dramatically abolished the antitumoral activity of cannabinoids against subcutaneous HCC xenografts. Furthermore, D 9 -THC and JWH-015 efficiently reduced ascites development and AFP expression in an orthotopic model of HCC, which also paralleled mTORC1 inhibition, AMPK activation and autophagy stimulation in those tumors. Our data represent the first evidence for the antiproliferative action of cannabinoids in HCC cells in vivo and support that the ability of cannabinoids to inhibit mTORC1, stimulate AMPK and enhance autophagy could be therapeutically exploited for the management of HCC.
Materials and Methods
Reagents. D
9
-THC was obtained from GW Pharm GmbH (Frankfurt, Germany) and JWH-015 was purchased to Sigma (St. Louis, MO, USA). The CB 1 antagonist SR-141716 and the CB 2 antagonist SR-144528 were kindly provided from SanofiSynthelabo (Paris, France). The anti-LC3 polyclonal antibody was obtained from MBL International (Woburn, MA, USA) and the anti-pS6, pAKT-ser473, pACC, ACC, peIF2a, pAMPK and AMPK polyclonal antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). The anti-caspase-3 antibody and 3-MA were purchased to Sigma. The inhibitors E64d and PA were purchased to Roche Diagnostics (Mannheim, Germany). The CaMKKa/b inhibitor STO609 was Cell cultures. Human HCC HepG2 cells (ATCC, HB-8065) (Rockville, MD, USA) were cultured according to suppliers. The human hepatoma cell line HuH-7 was kindly supply by Dr. Lisardo Boscá (IKnstituto de Investigaciones Biomédicas Alberto Sols, Madrid, Spain). Cells were routinely growth in DMEM/10% FBS supplemented with 1% non-essential amino acids and 100 IU/ml penicillin G sodium, 100 mg/ml streptomycin sulfate, 0.25 mg/ml amphotericin B (Invitrogen, Paisley, UK). One day before the experiments, the medium was changed to 0.5% FBS medium. Experiments were carried out when cell monolayers were 80% confluent.
RT-PCR analysis. Total RNA was isolated from cells by Trizol Reagent from Gibco (Invitrogen, Carlsbad, CA, USA) according to manufacturer's protocol. One microgram total RNA was retrotranscribed to cDNA with the M-MLV Reverse transcriptase kit (Life Technologies, Carlsbad, CA, USA). Two microliters of RT reaction were then PCR amplified with specific primers for CB 1 : sense primer, 0 -GAGCATACTGCAGAATGCAAACACC-3 0 (for amplification of a 333-bp product for human CB 2 ) . PCR products were analyzed by electrophoresis on ethidium bromidestained 2% agarose gels and DNA was detected by exposure under UV light.
Western blot. After different treatments according to the experiments cells were lysed in ice-cold lysis buffer (50 mM Tris (pH 7.4), 0.8 M NaCl, 5 mM MgCl 2 , 0.1% Triton X-100, 1 mM PMSF, 10 mg/ml soybean trypsin inhibitor, 1 mg/ml aprotinin and 5 mg/ml leupeptin), and cleared by microcentrifugation. Equivalent protein amounts of each sample were separated on SDS-PAGE gels and blotted to PVDF transfer membrane. After blocking with 5% skim dried milk, immunoblot analysis was performed followed by enhanced chemo luminescence detection.
Cell viability assay. Cells in logarithmic phase were cultured at a density of 5000 cells per cm 2 in a 12-well plate. The cells were exposed to various concentrations of D 9 -THC and JWH-015 for indicated times. The 3-[4,5-dimethylthiazolyl-2] 2,5-diphenyl-tetrazolium bromide (MTT) cell viability assay was used to evaluate the effects of cannabinoids on cell growth and to determine the IC 50 .
Confocal microscopy. After 48 h in culture, the cells were fixed in 4% paraformaldehyde in PBS and incubated with 0.1% Triton X-100 for permeabilization. Immunolabeling with the anti-LC3 polyclonal antibody was performed by incubation siRNA transfections. Cells were seeded at 2 Â 10 5 cells/35 mm well the day before transfection. Cells were then transfected in 1 ml OPTIMEN containing 4 mg Lipofectamine 2000 (Invitrogen), with 100 nM siRNA duplexes or control scrambled RNA according to the manufacturer's protocols. At 24 h after transfection, the medium was removed and replaced for DMEM containing 10% fetal bovine serum. Cells were then treated with cannabinoids for 48 h and used for MTT cell viability assays.
For each transfection, the following sequences were used: 0 -AAATCAGTTATGGTTCCTTTGGTC-3 0 . Amplifications were run in a 7900 HT-Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Each value was adjusted by using 18S RNA levels as a reference.
Animal care and handling. Athymic nude (nu/nu) 5-week-old male mice were obtained from Harlan Iberica Laboratory (Barcelona, Spain) and maintained under specific pathogen-free conditions with the approval of the Institutional Animal Care and Use Committee of Alcala University. All animal studies were conducted in accordance with the Spanish institutional regulation for the housing, care and use of experimental animals and met the European Community directives regulating animal research. Recommendations made by the United Kingdom coordinating Committee on Cancer Research (UKCCCR) have been kept carefully.
In vivo studies. To study the in vivo antitumor activity of cannabinoids, hepatocarcinoma tumors were induced in athymic mice by subcutaneal injection or by liver implantation. Mice were injected subcutaneously in the right flank with 10 Â 10 6 HepG2 or HuH-7 cells in 0.1 ml of PBS þ 0.5% BSA. At 2 weeks after transplantation, tumors had grown to an average volume of 150 mm 3 . Mice were then divided into different experimental groups of eight animals each, which received the following treatments as subcutaneous injections according to the experiment: saline (control); 15 mg/kg b.w. D 9 -THC; 1.5 mg/kg b.w. JWH-015; and 1 mg/kg b.w. 3-MA. The injection was repeated every day and treatment was continued for 15 days. Tumor volumes were monitored every day using calliper measurements and were calculated by the formula: (4p/3) Â (w/2) 2 Â (l/2). The body weight of the animals was recorded daily. For in vivo Atg5 knockdown, xenograft tumors were induced as indicated and 1 nmol specific Atg5 atelocollagencomplexed siRNA or control siRNA was injected peritumorally on days 1 and 7 of the treatment. Mice were treated daily for 15 days with saline, 15 mg/kg b.w. D When tumor cells were implanted in the liver, the treatments were initiated 1 week after cells injection and administered intraperitoneally. Eight animals were used in each experimental group. The study was performed for 10 days to minimize the trauma of the host animals according to UKCCCR recommendations. At the end of the treatment, the animals were killed and xenografted tumors and livers weighted and frozen.
Statistical analysis. Cell viability data were expressed as the mean ± S.D. and evaluated by Student's t-test. Differences were considered significant when the P-value was less than 0.05.
